Chris Beaver joins Pharmanet as Director, Immunochemistry Services
PharmaNet Development Group, Inc. announced that Chris Beaver, PhD has joined the Company as Director, immunochemistry services. Dr. Beaver is responsible for leading the immunochemistry team within the Company’s bioanalytical laboratories and expanding its large molecule services, including assay development and sample analysis for biomarker, ELISA, radioimmunoassays, immunogenicity and cell-based assays.
Dr. Beaver’s appointment strengthens PharmaNet’s offerings in large molecule bioanalytical services to support the growing interest in biologics and biosimilars within the pharmaceutical industry. PharmaNet has two GLP-compliant bioanalytical laboratories which are located in Princeton, New Jersey and Quebec City, Canada.
Previously, Dr. Beaver served as Scientific Director of Ligand Binding/Cell Based Assays at another clinical research organization with macromolecule bioanalysis operations. He completed his Ph.D. in Neuroscience at Dalhousie University in Halifax, Canada, followed by post-doctoral training at Yale University. Dr. Beaver is published in multiple scientific publications, including Drug Discovery World and Nature Neuroscience.
Most read news
Other news from the department people
These products might interest you

Systec H-Series by Systec
Safe, reproducible and validatable sterilization of liquids, solids and waste
Autoclaves with 65-1580 liters usable space, flexibly expandable for various applications

Whatman™ folded filter papers by Cytiva
Whatman folded filter papers
Convenient folded formats speed up your sample preparation

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
More news from our other portals
See the theme worlds for related content
Topic World Cell Analysis
Cell analyse advanced method allows us to explore and understand cells in their many facets. From single cell analysis to flow cytometry and imaging technology, cell analysis provides us with valuable insights into the structure, function and interaction of cells. Whether in medicine, biological research or pharmacology, cell analysis is revolutionizing our understanding of disease, development and treatment options.

Topic World Cell Analysis
Cell analyse advanced method allows us to explore and understand cells in their many facets. From single cell analysis to flow cytometry and imaging technology, cell analysis provides us with valuable insights into the structure, function and interaction of cells. Whether in medicine, biological research or pharmacology, cell analysis is revolutionizing our understanding of disease, development and treatment options.
Last viewed contents

Study reveals effects of chemoradiation in brains of glioblastoma patients
Trophos announces positive interim review in pivotal study of olesoxime in Spinal Muscular Atrophy
Amarillo Biosciences Publishes Reviews on Oral Interferon
Deadly candidiasis must be addressed swiftly to help vulnerable patients
William_Henry_Harvey

Intestinal inflammation: immune cells protect nerve cells after infection - New findings on the functions of the gut-brain axis
Mitsui Chemicals to Consolidate its Three Agrochemicals Subsidiaries
Bristol-Myers Squibb to Acquire Medarex

ANTABIO Raises €25 Million in Series B Financing - The financing will be used to support the clinical development of a next generation antibacterial combination
These boosts are made for walkin' - Study reveals that movement kicks visual system into higher gear
BASF sells marine biopolymers business to Seagarden ASA
